Business
SCYNEXIS's Ibrexafungerp Shows Favorable Clinical Activity in Resistant Fungal Infections, Including Candida auris Cases from the CARES Study, in Data to be Presented at the 29th ECCMID
JERSEY CITY, N.J., April 3, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat
About this update from Scynexis, Inc.
[{"type":"text","content":"JERSEY CITY, N.J., April 3, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced data demonstrating the potential use of ibrexafungerp as an agent to address multiple serious fungal infections, including many that have shown resistance to existing therapies. The collection of data will be presented in one oral and five poster presentations at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 13-16, 2019, in Amsterdam, Netherlands. \n\"We are pleased and proud to have a total of six presentations, including three late-breakers, accepted by ECCMID 2019, contributing to a growing body of evidence supporting the strong clinical activity of oral ibrexafungerp in difficult-to-treat and resistant Candida infections and its versatility in addressing unmet needs in multiple settings,\" said David Angulo, M.D., Chief Medical Officer of SCYNEXIS. \"Our ability to enroll and successfully treat patients in the FURI and CARES studies shows that there is a clear unmet medical need for a novel and more potent antifungal therapy, particularly an oral agent, to treat patients with these devastating fungal infections.\"\nIbrexafungerp, the first representative of a novel family of compounds referred to as \"fungerps\" (antifungal triterpenoids), is being developed for oral and intravenous (IV) administration and is in clinical development for the treatment of several serious fungal infections, including vulvovaginal candidiasis (VVC), invasive candidiasis (IC), invasive aspergillosis (IA) and refractory invasive fungal infections.\nECCMID, as one of the world's premier clinical microbiology and infectious disease events, brings together experts to present their latest findings, guidelines and experiences. Details of the six ibrexafungerp presentations are as follows:\nOral Presentation\nTitle: Favorable Response to Oral Ibrexafungerp (formerly SCY-078) in Patients with Refractory Fungal Diseases, Interim Analysis by Pathogen from a Phase 3 Open-label Study (FURI) Presenter: Oliver Cornely, MDDate and Time: Tuesday, April 16, from 11:00-12:00 CETOral Presentation #: L0010 Session: Recent clinical trials\nThe presentation showcases results from the first interim analysis of 20 ...